Phase II Trial of Hypofractionated Radiotherapy and Immunochemotherapy in Primary Refractory Diffuse Large B-Cell Lymphoma: Preliminary Results and Insights from Digital Spatial Profiling.

MedComm (2020) · 2025 · PMC12103654 · PMID 40416596

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Accumulating evidence indicates that the residual tumor (defined as refractory) burden is a highly significant prognostic factor, irrespective of whether systemic or localized therapies are used [ 33 , 34 , 35 , 36 ].

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.